Rhode Island Medicaid and GLP-1s: Weight-Loss Coverage Ended October 1, 2026

No, not for weight loss anymore. On October 1, 2026, Rhode Island Medicaid stopped paying for Wegovy, Zepbound, Saxenda or Foundayo when weight loss is the only reason for the prescription.^[1] It did not end all coverage: diabetes drugs continue with prior authorization, and Tufts Health RITogether, Neighborhood Health Plan and UnitedHealthcare all keep Wegovy for heart disease and MASH and Zepbound for sleep apnea.^[3][15][16]

What changed in Rhode Island Medicaid on October 1, 2026?

The state budget for fiscal 2027 authorized the health secretary to remove GLP-1 coverage, except when prescribed to treat type 2 diabetes.^[2] Federal Medicaid law does not require states to cover weight-loss drugs, so this was the state’s call, as it was next door in Connecticut, where a 2025 budget act removed a coverage mandate.^[9] The American Diabetes Association read the budget the same way when it passed in June 2026, describing coverage limited to people with type 2 diabetes.^[4] A statement from obesity groups, quoting the governor’s budget, put the savings at $6.3 million in general revenue and $20.3 million from all funds.^[6]

The memo that implemented it is narrower. The Executive Office of Health and Human Services told providers on August 5, 2026 that coverage ends for four named drugs when weight loss is the sole reason they are prescribed.^[1] It added that someone who needs one of them for another reason requires a new prior authorization with clinical documentation.^[1] So the practical rule follows the memo, and the reason on the prescription now decides the outcome.

Were people already on Wegovy or Zepbound allowed to stay on it?

We found no grandfathering in the documents. At Tufts Health RITogether, authorizations for weight loss were end-dated to September 30, 2026, and members were to be told by notice.^[3] The state’s memo asked providers to review affected members’ treatment plans and discuss alternatives before the change.^[1] We did not find a state count of how many members lost coverage.

Stopping has consequences a prescriber should plan for, so someone who lost coverage should raise it soon, not wait until the last pen. Our review of what happens when you stop a GLP-1 covers weight regain and how it tends to unfold.

Can you still get Wegovy for heart disease on Rhode Island Medicaid?

Yes, at all three plans, with a new prior authorization. Tufts’ notice keeps Wegovy, in injection or tablet form, for adults who have heart or artery disease and carry excess weight, which matches the labeled use.^[3][10] Neighborhood and UnitedHealthcare posted criteria that took effect October 1. Both ask for a BMI of 27 or more, a past heart attack, stroke or symptomatic peripheral artery disease, standard heart drugs or a reason the patient cannot take them, a diet and activity plan, and no type 2 diabetes.^[15][16] UnitedHealthcare also sets a minimum age of 45, excludes an A1C of 6.5% or more and class IV heart failure, and approves 12 months at a time; Neighborhood approves six months and points people with diabetes to Ozempic for heart protection.^[16][15]

Does Rhode Island Medicaid still cover Zepbound for sleep apnea?

Yes, at all three plans, for adults with obesity whose obstructive sleep apnea is moderate or severe (by comparison, Kentucky Medicaid requires a three-month CPAP trial first).^[3][11] The two plans whose criteria we read ask for more than the label does, including a CPAP history or a reason CPAP cannot be used.^[15][16]

The background on both uses is in Zepbound for sleep apnea and GLP-1s and fatty liver. A prescriber should only request one of these routes when the diagnosis is real and documented.

Does Rhode Island Medicaid still cover Ozempic and Mounjaro for diabetes?

Yes. Tufts says these drugs continue with prior authorization and that members who already have approval are not affected, though switching to a different one needs a new request.^[3] The state told estimators in May 2026 that its fee-for-service rule asks for metformin or a TZD drug within the past 90 days, and Neighborhood’s current policy asks for three months of metformin at the highest tolerated dose, up to 2 grams a day, unless metformin is unsuitable.^[5][17] Prediabetes is not a route: Neighborhood has no criteria for it.^[5]

What about children and teenagers?

Federal Medicaid rules for people under 21 still apply. The state says every request for that age group must be reviewed for medical necessity under Medicaid’s children’s benefit, known as EPSDT.^[1] That is a review and not a promise of approval, and Tufts said its members would be assessed under a general criteria document posted October 1.^[3]

How do you appeal a denial from Rhode Island Medicaid?

• Plan appeal. Federal rules give managed care members 60 calendar days from the notice.^[7]
• State fair hearing. After the plan decides, federal rules set a window of 90 to 120 calendar days, and your notice gives the date.^[8]

An appeal cannot restore coverage the budget removed. It can succeed when a request for another use was wrongly treated as weight loss, or when the clinical record was incomplete. If your denial letter names a different deadline, follow the letter. Our guide on getting a GLP-1 covered has more on what to send.

What are the options after losing coverage?

Cash is the main path. Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s self-pay Zepbound.^[12][13] Lilly’s savings card excludes government programs, so read each offer’s terms.^[12] People also on Medicare may qualify for the Medicare GLP-1 Bridge through December 31, 2027, at a BMI of 35, or 30 with certain conditions.^[14] The guide to the lowest GLP-1 prices without insurance compares the options, and our national page on Medicaid and Zepbound tracks where other states stand.